MEDIA

Nanexa publishes year-end report for 2021

17 February, 2022
- Regulatory
Download attachment

Additional evaluation agreement and positive results in preclinical investigation of NEX-18

Significant events during the fourth quarter 2021

  • Nanexa received a decision from the Swedish Financial Supervisory Authority to pay a penalty of SEK 1,000,000 in relation to an incident that occurred in 2017.
  • Nanexa signed an additional Material Transfer and Feasibility Study Agreement with one of its existing customers for the evaluation of the PharmaShell® technology with a specific biological drug substance.
  • Additional preclinical studies were initiated in October to investigate the cause of the moderate skin reactions seen in the company's Phase I study of NEX-18, a long-acting formulation of azacitidine based on PharmaShell.

Significant events after the end of the period

  • Nanexa was granted a patent in the US (US 11,214,865 B2) for an ALD reactor adapted for large-scale production of PharmaShell-coated drugs.
  • Nanexa announced that the company’s preclinical investigation indicates the cause of and a potential solution to the moderate skin reactions that arose in the clinical study with NEX-18. With these results, Nanexa is expanding its preclinical program to optimize the formulation of NEX-18, and the project is expected to re-enter clinical phase next year.

Summary of the reporting period 1 October – 31 December 2021

  • Turnover amounted to: TSEK 670 (549)
  • Operating profit (EBIT) amounted to: TSEK -13,045 (-7,768)
  • Profit after tax amounted to: TSEK -13,087 (-7,814)
  • Earnings per share amounted to: SEK -0.26 (-0.37)
  • Cash flow for the period amounted to: TSEK -14,139 (-13,300)
  • Cash and cash equivalents at end of period: TSEK 105,660 (12,691)

Summary of the reporting period 1 January – 31 December 2021

  • Turnover amounted to: TSEK 2,374 (2,367)
  • Operating profit (EBIT) amounted to: TSEK -35,821 (-21,489)
  • Profit after tax amounted to: TSEK -35,999 (-21,736)
  • Earnings per share amounted to: SEK -1.01 (-1.09)
  • Cash flow for the period amounted to: 92 969 (1 313) TSEK
  • Cash and cash equivalents at end of period: TSEK 105,660 (12,691)
  • The Board of Directors proposes that no dividend is paid

Figures in brackets refer to the corresponding period in the previous year.

Investor presentation

Webcast and teleconference with Q&A session will be held on February 17, 2022, at 2:30 pm (CET), with chairman of the board Göran Ando, CEO David Westberg and board member Bengt Gustavsson.

Webcast: https://tv.streamfabriken.com/nanexa-q4-2021
Teleconference: SE: +46856642706 | UK: +443333009260 | US: +16467224902

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa devlops its own products and has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-02-17 08:00 CET.

Attachments

Nanexa Year End Report 2021